Key priorities for Switzerland’s Basilea Pharmaceutica Ltd. this year include pursuing the US Phase III study of the fifth-generation cephalosporin ceftobiprole in serious infections, obtaining interim clinical trial results for its lead oncology candidates derazantinib and lisavanbulin, and helping partner CR Gosun launch ceftobiprole in China.
The Basel, Switzerland-based drug development company expects to complete enrolment into the Phase III ERADICATE study of the fifth-generation cephalosporin, ceftobiprole in Staphylococcus aureus bacteremia by the end of this year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
